RxDoctor Payments Data

Kelly Felps, MD

Internal Medicine · Fort Worth, TXNPI 1205804366

Payments from drug & device makers

$1,252in general payments, 2019–2025

Across 73 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$232
  • AbbVie$175
  • GSK$104
  • Pfizer$90
  • Boehringer Ingelheim$78
  • Biohaven Pharmaceutical Holding Company Ltd.$66
  • plus $506 from 18 others

What the payments were for

  • Food & beverage$1,252100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,252 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,223
Medicare patients
168
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$72,629
EliquisApixaban57$64,481
JanuviaSitagliptin Phosphate24$28,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$20,709
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,976
SymbicortBudesonide/Formoterol Fumarate11$4,064
SynthroidLevothyroxine Sodium53$3,504
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,204
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,717
Albuterol Sulfate HfaAlbuterol Sulfate81$2,365
Rosuvastatin Calcium197$2,167
Tamsulosin Hcl116$2,105
Novolog FlexpenInsulin Aspart11$1,983
Atorvastatin Calcium199$1,952
Metoprolol Succinate129$1,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$232$72,62957 claims
PfizerEliquis$90$64,48157 claims
MerckJanuvia$61$28,07424 claims
GSKTrelegy Ellipta$104$20,70917 claims
AstraZenecaSymbicort$28$4,06411 claims
AbbVieSynthroid$175$3,50453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →